A Long-term Follow-up Study in Patients Who Received BEAM-101
About this study
This is a Long-term Follow-up (LTFU) study in patients who received BEAM-101 in the parent study (Study BTX-AUT-001). Eligible patients who received BEAM-101 will be asked to participate in this LTFU study prior to completing Study BTX-AUT-001. Patients who enter into this study will be followed for 13 years (a total of 15 years after receiving BEAM-101).
- Condition
- Hemoglobinopathy, Sickle Cell Disease
- Tested
- Long-Term Follow-up Study of patients who received BEAM-101
- Sponsor
- Beam Therapeutics Inc.
Who can join
- Age
- 14 to 37 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 14 years
- Maximum age: 37 years
- Study condition: Hemoglobinopathy, Sickle Cell Disease
- Have received BEAM-101 in Study BTX-AUT-001 and are in the process of completing that study's end-of-study (EOS) visit.
- Provide signed, written informed consent according to local institutional review board (IRB)/independent ethics committee (IEC) and institutional requirements.
Exclusion 1
- There are no exclusion criteria for this study.
Where
17 sites, 17 recruiting
Boston Children's Hospital
Boston, Massachusetts, United States
Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston
Atlanta, Georgia, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Medical University of South Carolina
Charleston, South Carolina, United States
University Hospitals Clevland Medical Center
Cleveland, Ohio, United States
The Clevland Clinic Foundation
Cleveland, Ohio, United States
and 11 more sites on ClinicalTrials.gov
Contact
-
Medical Information
+1 857-327-8641 clinicalinfo@beamtx.com
Potential match only. Final eligibility is determined by the study team.